Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Spectral AI Appoints Jeremiah Sparks as Chief

Commercialization Officer

Experienced Burn Industry Executive Champions

Pivot to Commercialization

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral

AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company") , an artificial intelligence (AI) company focused

on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A.

Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing

and business strategy. Mr. Sparks will be responsible for both domestic and international product commercialization.

"We are thrilled to have Jeremiah join the

company as we move towards commercialization of DeepView," said Peter M. Carlson, CEO of Spectral AI. "With his strong track

record, most recently as Vice President of Global Strategy at AVITA Medical, he will hit the ground running as we drive market entry of

Spectral AI's products, allowing our innovative wound management solutions to reach physicians and the patients for whom they provide

Mr. Sparks' diverse experience includes driving market assessments

and commercialization plans both domestically and on a global scale. He has consistently increased return of investment at MedTech companies

through strategic marketing approaches. Sparks has also developed successful commercial teams across multiple ventures and managed market

access strategies, including payer and pricing strategies over various geographies. He has worked with U.S. government agencies to bring

innovative therapies for skin restoration targeted to improve burn wound care. Mr. Sparks has previously launched new products at Johnson

& Johnson, Healthpoint, and Allergan on national and global scales.

have me well poised to bring Spectral AI's technology to market across a broad range of locations, demographics and clinical indications,"

Mr. Sparks said. "This groundbreaking technology holds promise for several applications and I am excited to help the team deliver

this advancement in wound care management to as many patients as possible."

Mr. Sparks earned his Master of Business Administration

from Thunderbird Graduate School of Global Management. He holds a Bachelor of Arts degree in International Relations from Brigham Young

University and has authored multiple Health Economics publications focused on cost effectiveness and outcomes with an emphasis on real

world evidence throughout his career.

Spectral AI, Inc. is a Dallas-based predictive

AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving

patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the

Unknown " with its DeepView System. DeepView is a predictive device that

offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention.

With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide

faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information

about DeepView , visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are

"forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private

Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives,

initiatives and financial outlook. When used in this press release, the words "estimates," "projected,"

"expects," "anticipates," "forecasts," "plans," "intends,"

"believes," "seeks," "may," "will," "should," "future,"

"propose" and variations of these words or similar expressions (or the negative versions of such words or expressions)

are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance,

conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of

which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the

forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.

Investors should carefully consider the foregoing factors and the other

risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the

Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties

that could cause actual events and results to differ materially from those contained in the forward- looking statements.